Skip to main content
. 2023 Jun 22;6:660. doi: 10.1038/s42003-023-05045-0

Fig. 4. AXL inhibition sensitises BRCA mutant cells to PARP1 inhibition.

Fig. 4

Combination treatment of R428 with Olaparib in a BRCA2 mutant PEO1, b BRCA1/2 mutant RMG5, c SKOV3 and d HeyA8. e Combination index of R428 and Olaparib. f Dose reduction index of Olaparib. Fa fraction affected.